You can buy or sell ACOR and other stocks, options, ETFs, and crypto commission-free!
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. Read More The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.
Ardsley, New York
52 Week High
52 Week Low
Yahoo FinanceMay 9
Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. NASDAQ and Russell 2000 indices were already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points in the fourth quarter. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their portfolios in smaller cap stocks. We have been receiving ind...
Current Trend: Acorda Therapeutics (NASDAQ: ACOR)
Acorda Therapeutics is in the biotechnology industry and is part of the healthcare sector. The company CEO is Ron Cohen. Acorda Therapeutics Inc is a biopharmaceutical company. It is engaged in the identification, development and commercialization of novel therapies for the treatment of neurological disorders. Previous Intraday Trading Performance: The ACOR stock showed a previous change of 1.03% with an open at 11.57 and a close of 11.75. It reached an intraday high of 11.97 and a low of 11.41. SeekingA...
Yahoo FinanceMay 7
See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
Acorda Therapeutics Inc NASDAQ/NGS:ACOR View full report here! Summary ETFs holding this stock are seeing positive inflows Bearish sentiment is moderate Economic output in this company's sector is expanding Bearish sentiment Short interest | Neutral Short interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among inves...
Expected Aug 1, Pre-Market